What it's for (Indications)
- Ceftriaxone is indicated for severe respiratory, genitourinary (urinary and genital system), bone, joint, and abdominal infections, sepsis (a life-threatening condition in response to infection), meningitis (inflammation of meninges), and for the prevention of infection after surgery.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Ceftriaxone is administered intravenously (IV) or intramuscularly (IM). For IV administration, the powder is mixed with a liquid or supplied as a premixed product, then slowly injected over 30 to 60 minutes. It is crucial to use a compatible diluent and ensure proper preparation and storage, especially for home use. Do not use diluents containing calcium (e.g., Ringer's solution, Hartmann's solution) for reconstitution or further dilution. The recommended dose is typically 1 to 2 grams, and the single day dose should not exceed 4 grams. The duration of therapy varies by infection type: commonly 10 days for Streptococcus bacterial infections, 7 to 14 days for meningitis, 10 to 14 days for syphilis, and 3 days for middle ear infection. It is essential to complete the full prescribed course of treatment, even if symptoms subside, to prevent antibiotic resistance. For best effect, administer at the same time daily. Store at room temperature (25°C) and away from light. |
Safety & Warnings
Common Side Effects
- Ceftriaxone is generally well tolerated.
- Common adverse reactions include injection site reactions (pain, induration, tenderness, inflammation, irritation, hard swelling, warmth, tightness, phlebitis), rash, pruritus, fever, chills, eosinophilia, thrombocytosis, leukopenia, and genital fungal infection.
- Less frequently reported or rare side effects include nausea, vomiting, diarrhea (including pseudomembranous colitis), headache, sleepiness, unusual weakness or tiredness, abdominal pain, raised liver enzymes, glucosuria (glucose in urine), oliguria (decreased urine output), hematuria (blood in urine), bronchospasm (spasm of airways), urinary and biliary precipitates, nephrolithiasis (kidney stones), pancreatitis (inflammation of pancreas), hemolytic anemia (red cells destroyed faster than made), lymphopenia, neutropenia, thrombocytopenia, prolongation of prothrombin time, positive Coombs test, granulocytopenia (decrease in granulocyte count), and vaginal discharge and itching.
Serious Warnings
- Black Box Warning: Fatal reactions have been reported in neonates (under 28 days of age) who received intravenous ceftriaxone and calcium-containing solutions. Ceftriaxone is contraindicated in premature neonates up to a postmenstrual age of 41 weeks and in hyperbilirubinemic neonates due to the risk of bilirubin encephalopathy. Ceftriaxone must not be co-administered simultaneously with intravenous calcium-containing solutions, including continuous calcium-containing infusions such as parenteral nutrition, via a Y-site in any patient, due to the risk of ceftriaxone-calcium precipitation. A potentially fatal arrhythmia has also been observed in patients who have received a rapid bolus injection with a central venous line.
- Administer ceftriaxone with caution in patients with a history of penicillin or other beta-lactam antibiotic allergy, as there is an increased risk of hypersensitivity reactions.
- Patients with a history of colitis or other gastrointestinal diseases, severe renal or hepatic impairment, or hemolytic anemia should use ceftriaxone with caution; dose adjustments may be necessary in kidney disease, and the maximum single day dose should not exceed 4 grams.
- For patients with kidney failure, the dose should not exceed 2 grams.
- Prolonged treatment can lead to granulocytopenia, and full blood count monitoring is advised.
- It may also alter blood clotting time.
- Extended or repeated therapy can lead to fungal or bacterial overgrowth by non-susceptible microorganisms.
- Ceftriaxone should not be mixed or administered simultaneously via the same IV line with calcium-containing solutions (e.
- g.
- , Ringer's or Hartmann's solution) due to the risk of precipitation, particularly in neonates.
- In patients other than neonates, sequential administration is possible if lines are thoroughly flushed.
- Rapid bolus injection, especially with a central venous line, has been associated with potentially fatal arrhythmia.
- To reduce irritation, infusion sites should be switched.
- Pregnant women should only use this medication if absolutely necessary and under medical advice, with a thorough risk/benefit analysis.
- While minimal amounts are found in breast milk, caution is advised for lactating mothers, and it should only be used if the benefit outweighs the risk to the baby.
- Patients may experience sleepiness, dizziness, or unusual weakness; therefore, caution is advised when driving or engaging in activities requiring mental alertness.
- Avoid alcohol consumption while on this medication.
- The full prescribed course of therapy should be completed to prevent antibiotic resistance.
- Elderly patients may be at higher risk for side effects and may require a lower dose.
- Ceftriaxone may interact with anticoagulants, chloramphenicol, and aminoglycosides, requiring proper monitoring.
- It can also interfere with certain lab tests, including galactosemia tests (blood and urine) and Coombs' test.
- Keep out of reach of children.
How it Works (Mechanism of Action)
Ceftriaxone is a bactericidal agent that works by inhibiting bacterial cell wall synthesis. It achieves this by attaching to one or more of the penicillin-binding proteins, leading to the breakdown of the bacterial cell wall and arresting bacterial growth. Ceftriaxone also exhibits activity in the presence of some beta-lactamases (both penicillinases and cephalosporinases) produced by Gram-negative and Gram-positive bacteria.